- Pre-2000: Collaboration Agreement between Bayer AG and Hong Kong University of Science and Technology (HKUST) to develop new drugs for malaria.
- 2000: Bayer selects Artemisone as a development candidate (designated BAY 44-9585).
- 2000-2002: Project transferred to Bayer HealthCare AG (BHC); involvement of Medicines for Malaria Venture (MMV).
- 2002-2005: Three phase I clinical trials conducted in Germany, one phase IIa clinical trial conducted in Thailand.
- 2006: BHC discontinues anti-infective efforts in connection with takeover by Schering AG.
- 2007: Asset transfer of data, know-how, and patents from BHC to HKUST.
- 2008-2011: API from Bayer undergoes additional studies under MMV.
- 2007: First field reports of artemisinin drug resistance emerge.
- 2008: First case study of an artemisinin used to treat CMV published by Dr. D. Wolf (CMO).
- 2011: Further evaluation of Artemisone’s resistance and transmission-blocking activities in malaria.
- 2014: Development under MRC Flagship Project Award granted to Dr. R. Haynes, with groups in South Africa, Australia, USA, Singapore, and Europe.
- 2016: Patents, data, and know-how licensed to Artemis Therapeutics, Inc. (USA).
Artemisone for Other Infectious Diseases
Artemisone is a broad-acting anti-infective agent and may have utility in other diseases and conditions, including but not limited to, as an antiparasitic, antiviral, or anticancer agent.
Artemis intends to explore Artemisone as a treatment for additional human and/or animal diseases.